## **Core Concept**
The question targets the understanding of direct-acting antivirals (DAAs) used in the treatment of Hepatitis C Virus (HCV) infections. DAAs are a class of medications that directly target specific steps in the HCV replication cycle, offering a more effective and better-tolerated alternative to traditional interferon-based therapies.

## **Why the Correct Answer is Right**
Ribavirin is a nucleoside analogue that exerts its antiviral effect through multiple mechanisms, including immune modulation and direct antiviral activity. However, its primary use in HCV treatment has been in combination with interferon (early treatments) or as part of some DAA regimens, not as a standalone direct-acting agent in the same vein as the newer DAAs like protease inhibitors (e.g., , , ), polymerase inhibitors (e.g., ), and others that directly target HCV proteins.

## **Why Each Wrong Option is Incorrect**
- **Option A:** is a direct-acting antiviral agent. It is a protease inhibitor that targets the NS3/4A protease of HCV, crucial for viral replication.
- **Option B:** is also a direct-acting antiviral agent. It acts as a polymerase inhibitor, specifically targeting the NS5B polymerase of HCV.
- **Option D:** is another direct-acting antiviral agent. It is a NS5A inhibitor, which disrupts the HCV replication complex.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that while Ribavirin (Option C) has been used in the treatment of HCV, often in combination with other agents, it is not classified strictly as a direct-acting antiviral in the same category as the more recently developed drugs that specifically target viral enzymes or proteins.

## **Correct Answer:** . Ribavirin